These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. Todd NV; Morrow J; Doh-ura K; Dealler S; O'Hare S; Farling P; Duddy M; Rainov NG J Infect; 2005 Jun; 50(5):394-6. PubMed ID: 15907546 [TBL] [Abstract][Full Text] [Related]
7. Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate. Terada T; Tsuboi Y; Obi T; Doh-ura K; Murayama S; Kitamoto T; Yamada T; Mizoguchi K Acta Neurol Scand; 2010 Feb; 121(2):127-30. PubMed ID: 19804470 [TBL] [Abstract][Full Text] [Related]
8. Medicines committee felt unable to recommend use of pentosan polyphosphate in vCJD. Gould M BMJ; 2003 Oct; 327(7418):770. PubMed ID: 14525869 [No Abstract] [Full Text] [Related]
9. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Farquhar C; Dickinson A; Bruce M Lancet; 1999 Jan; 353(9147):117. PubMed ID: 10023899 [No Abstract] [Full Text] [Related]
10. Second vCJD patient to receive experimental treatment. Dyer C BMJ; 2003 Oct; 327(7420):886. PubMed ID: 14563724 [No Abstract] [Full Text] [Related]
11. Small improvement seen in teenager with vCJD. Mayor S BMJ; 2003 Oct; 327(7418):765. PubMed ID: 14525852 [No Abstract] [Full Text] [Related]
12. [New knowledge about Creutzfeldt-Jakob disease can yield therapeutic possibilities]. Stølsmark T; Tysnes OB Tidsskr Nor Laegeforen; 2010 Mar; 130(6):601-4. PubMed ID: 20349004 [TBL] [Abstract][Full Text] [Related]
13. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Rainov NG; Tsuboi Y; Krolak-Salmon P; Vighetto A; Doh-Ura K Expert Opin Biol Ther; 2007 May; 7(5):713-26. PubMed ID: 17477808 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of up to 900 mg/day polysulfate sodium (elmiron) in patients with interstitial cystitis. Nickel JC; Forrest J; Barkin J; Payne C; Mosbaugh P Urology; 2001 Jun; 57(6 Suppl 1):122-3. PubMed ID: 11378111 [No Abstract] [Full Text] [Related]
16. Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt-Jakob disease. Groveman BR; Ferreira NC; Foliaki ST; Walters RO; Winkler CW; Race B; Hughson AG; Zanusso G; Haigh CL Sci Rep; 2021 Mar; 11(1):5165. PubMed ID: 33727594 [TBL] [Abstract][Full Text] [Related]
17. Protease-resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion. Honda H; Sasaki K; Minaki H; Masui K; Suzuki SO; Doh-Ura K; Iwaki T Neuropathology; 2012 Apr; 32(2):124-32. PubMed ID: 21801238 [TBL] [Abstract][Full Text] [Related]
18. Analysis of long-term Elmiron therapy for interstitial cystitis. Urology 1997;49(Suppl 5A):93-99. Sand PK; Winkler HA J Womens Health; 1998 Mar; 7(2):268-9. PubMed ID: 9555694 [No Abstract] [Full Text] [Related]
19. Creutzfeldt-Jakob disease: hopes for therapy. Pocchiari M; Ladogana A; Graziano S; Puopolo M Eur J Neurol; 2008 May; 15(5):435-6. PubMed ID: 18394045 [No Abstract] [Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium. Modi NB; Kell S; Simon M; Vargas R J Clin Pharmacol; 2005 Aug; 45(8):919-26. PubMed ID: 16027402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]